Macrophage polarizing oncolytic herpes simplex virus for cancer therapy
AssigneeResearch Institute At Nationwide Children's Hospital
InventorsChun-Yu Chen, Pin-Yi Wang, Timothy P. Cripe
Life of this patent
Estimating the term…
Abstract
This disclosure relates to a modified oncolytic herpes simplex virus (oHSV) comprising an expression cassette encoding a histidine-rich glycoprotein (HRG), and uses thereof. One promising avenue for the treatment of cancer is oncolytic virotherapy, e.g., oncolytic Herpes Simplex Virus (oHSV) which utilizes genetically modified viruses to selectively target and lyse cancer cells while sparing the normal cells. Oncolytic virotherapy is a safe and effective immunotherapeutic platform for different types of cancers.
Claims33
A modified oncolytic herpes simplex virus (oHSV) comprising an expression cassette encoding a histidine-rich glycoprotein (HRG), wherein the oHSV comprises an attenuated oHSV.
(canceled)
11-13. (canceled)
(canceled)
(canceled)
(canceled)
23-25. (canceled)
(canceled)
(canceled)
(canceled)
33-34. (canceled)
(canceled)
38-40. (canceled)
Dependencies are inferred from the claim text.